Tryp Therapeutics: Edison Open House Healthcare 2022

Tryp Therapeutics: Edison Open House Healthcare 2022

Tryp Therapeutics is leading psychedelic drug development beyond mental health.

• Tell us more about the company.
• Please explain the decision to focus on the unmet needs of eating disorders and pain.
• What is unique about Tryp’s formulation of psilocybin?
• What is the dosing schedule?
• What is your approach towards intellectual property?
• Do you think we have moved beyond the potential stigma around these types of products?
• Please explain the different drug candidates in your pipeline.
• What can investors expect over the next year?
• Please explain why you have chosen difficult conditions with a high unmet need.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free